Skip to main content

Table 2 Key Baseline Characteristics by Duration of CR/CRu

From: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

 

CR/CRu ≥ 12 months (n = 10)

CR/CRu < 12 months (n = 9)

P value

Male sex, n (%)

7 (70)

5 (56)

.65

Median age, years (range)

61.5 (47–78)

57.0 (37–74)

.43

ECOG performance status, n (%)

  0

3 (30)

4 (44)

.57

  1

6 (60)

3 (33)

  2

1 (10)

2 (22)

IPI score, n (%)

  < 2

2 (20)

1 (11)

1.00

  ≥ 2

8 (80)

8 (89)

Prior systemic therapies, n (%)

  1

2 (20)

3 (33)

.38

  2

3 (30)

3 (33)

  3

0

2 (22)

  4

3 (30)

1 (11)

  > 4

2 (20)

0

Best response to most recent prior therapy, n (%)

  CR/CRu/PR

2 (20)

6 (67)

.07

  < PR

8 (80)

3 (33)

Disease stage at diagnosis, n (%)

  I/II

0 (0)

4 (44)

.03

  III/IV

10 (100)

5 (56)

PTCL subtype, n (%)

  PTCL-NOS

5 (50)

5 (56)

.34

  AITL

4 (40)

1 (11)

  ALK-1–negative ALCL

1 (10)

3 (33)

Bone marrow involvement, n (%)

5 (50)

2 (22)

.35

Elevated LDH, n (%)

5 (50)

8 (89)

.14

Platelet count x 109/L, median (range)

199 (101–307)

172 (99–649)

.42

  1. Abbreviations: AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, CR complete response, CR/CRu confirmed/unconfirmed complete response, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, NOS not otherwise specified, PR partial response, PTCL peripheral T-cell lymphoma.